{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000067","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.722578+00:00","generated_at":"2026-05-21T01:33:08.170453+00:00","sec_items":["5.07","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Nurix Therapeutics annual meeting elects directors, ratifies auditor, passes say-on-pay","bullets":["All three Class II director nominees elected: Reinsdorf (43.57M for), Saltzman (50.30M for), Baynes (60.82M for).","Ratification of PricewaterhouseCoopers as independent auditor for FY2025 approved (64,950,599 for, 85,040 against).","Non-binding advisory vote on named executive officer compensation passed (49,788,975 for, 11,341,365 against).","Annual meeting held May 19, 2025; 65,056,197 shares (85.33% of voting power) constituted a quorum."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000067","json":"https://secwatch.observer/filing/0001549595-25-000067.json","markdown":"https://secwatch.observer/filing/0001549595-25-000067.md","text":"https://secwatch.observer/filing/0001549595-25-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000067/0001549595-25-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000067/nrix-20250519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T01:33:08.170453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}